# This Study Will Compare the Efficacy and Safety of SCT510A Administered by Intravitreal Injection (IVT) With Ranibizumab in Patients With wAMD

> **NCT05480293** · PHASE3 · UNKNOWN · sponsor: **Sinocelltech Ltd.** · enrollment: 446 (estimated)

## Conditions studied

- Wet Age-related Macular Degeneration

## Interventions

- **DRUG:** Ranibizumab
- **DRUG:** SCT510A

## Key facts

- **NCT ID:** NCT05480293
- **Lead sponsor:** Sinocelltech Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-02-14
- **Primary completion:** 2025-07-31
- **Final completion:** 2025-08-31
- **Target enrollment:** 446 (ESTIMATED)
- **Last updated:** 2023-02-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05480293

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05480293, "This Study Will Compare the Efficacy and Safety of SCT510A Administered by Intravitreal Injection (IVT) With Ranibizumab in Patients With wAMD". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT05480293. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*